Skip to content

Discover ✨Ask Topics Community 🎓Learn

PredictPal is a neutral, third-party aggregator of public prediction-market data. It is informational only — not affiliated with any platform, and it does not facilitate trading or hold funds. Market data is sourced from each platform’s public API and may be delayed.

Sources: Polymarket · Kalshi · Manifold · PredictIt · Hyperliquid · Myriad · Azuro · Limitless · Futuur · ForecastEx · InsightX · XO Market · Smarkets · SX Bet · Metaculus

Compare odds across venues·Resolved markets·How it works·Support·Privacy Policy·Terms of Service

Tech prediction markets & live odds — page 23 | PredictPal · PredictPal

💻

Tech prediction markets

AI milestones, product launches, and company outcomes priced by prediction markets.

🔭 Compare tech odds across venues →

All AI 2360 Tech Company Valuations 877 Big tech & chips 601 Space 448 Science 264 Through 40 Elevator 15 Software Engineering Trends 14 Space Development 9 Space Tech & Exploration ✨ 8 Software Industry Trends 5 Streamer 2

822 markets · page 23 of 35

Kalshi

Open

Will it be reported by any of the Source Agencies that general access to Fable 5 is disabled for US customers before Jul 31, 2026? — Before Jul 31, 2026

Yes1¢

No99¢

Yes ≈ 1% chance

$7.9K Vol▲ 0pts4d

Kalshi

‹ Prev1…2122232425…35Next ›

Open

Will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression before Jan 1, 2027? — Before Jan 1, 2027

Yes34¢

No66¢

Yes ≈ 34% chance

$2K Vol▲ 0pts5mo

Kalshi

Open

When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? — Before July 2027

Yes79¢

No21¢

Yes ≈ 79% chance

$8.6K Vol▼ 15pts11mo

Kalshi

Open

Will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression before Mar 1, 2027? — Before Mar 1, 2027

Yes59¢

No41¢

Yes ≈ 59% chance

$1.1K Vol▲ 0pts7mo

Kalshi

Open

When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? — Before 2028

Yes82¢

No18¢

Yes ≈ 82% chance

$786 Vol▲ 0pts1y

Kalshi

Open

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? — Before July 2027

Yes35¢

No65¢

Yes ≈ 35% chance

$1.9K Vol▲ 0pts11mo

Kalshi

Open

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? — Before October 2027

Yes52¢

No48¢

Yes ≈ 52% chance

$888 Vol▲ 0pts1y

Kalshi

Open

When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema? — Before 2028

Yes65¢

No35¢

Yes ≈ 65% chance

$536 Vol▲ 0pts1y

Kalshi

Open

Will the FDA approve CagriSema before Oct 1, 2026? — Before Oct 1, 2026

Yes21¢

No79¢

Yes ≈ 21% chance

$238 Vol▲ 0pts2mo

Kalshi

Open

Will the FDA approve CagriSema before Jan 1, 2027? — Before Jan 1, 2027

Yes75¢

No25¢

Yes ≈ 75% chance

$517 Vol▲ 0pts5mo

Kalshi

Open

Will the FDA approve CagriSema before Jul 1, 2027? — Before Jul 1, 2027

Yes84¢

No16¢

Yes ≈ 84% chance

$987 Vol▲ 0pts11mo

Kalshi

Open

Will the FDA approve CagriSema before Jan 1, 2028? — Before Jan 1, 2028

Yes76¢

No24¢

Yes ≈ 76% chance

$966 Vol▲ 0pts1y

Kalshi

Open

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Oct 1, 2026? — Before Oct 1, 2026

Yes36¢

No64¢

Yes ≈ 36% chance

$1K Vol▲ 0pts2mo

Kalshi

Open

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2027? — Before Jan 1, 2027

Yes64¢

No36¢

Yes ≈ 64% chance

$505 Vol▲ 0pts5mo

Kalshi

Open

Will the FDA approve camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation before Jan 1, 2028? — Before Jan 1, 2028

Yes77¢

No23¢

Yes ≈ 77% chance

$91 Vol▲ 0pts1y

Kalshi

Open

Will the FDA approve cytisinicline for smoking cessation before Jan 1, 2027? — Before Jan 1, 2027

Yes12¢

No88¢

Yes ≈ 12% chance

$91 Vol▲ 0pts5mo

Kalshi

Open

Will the FDA approve cytisinicline for smoking cessation before Jul 1, 2027? — Before Jul 1, 2027

Yes44¢

No56¢

Yes ≈ 44% chance

$568 Vol▲ 0pts11mo

Kalshi

Open

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2029? — Before Jan 1, 2029

Yes54¢

No46¢

Yes ≈ 54% chance

$474 Vol▲ 0pts2y

Kalshi

Open

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030? — Before Jan 1, 2030

Yes55¢

No45¢

Yes ≈ 55% chance

$401 Vol▲ 0pts3y

Kalshi

Open

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031? — Before Jan 1, 2031

Yes56¢

No44¢

Yes ≈ 56% chance

$98 Vol▲ 0pts4y

Kalshi

Open

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032? — Before Jan 1, 2032

Yes52¢

No48¢

Yes ≈ 52% chance

$71 Vol▲ 0pts5y

Kalshi

Open

When will the FDA approve retatrutide (LY3437943)? — Before Jul 1, 2028

Yes95¢

No5¢

Yes ≈ 95% chance

$28 Vol▲ 0pts1y

Kalshi

Open

When will the FDA approve retatrutide (LY3437943)? — Before Jan 1, 2029

Yes85¢

No15¢

Yes ≈ 85% chance

$74 Vol▲ 0pts2y

Kalshi

Open

Will the FDA approve VERVE-102 before Jan 1, 2030? — Before 2030

Yes58¢

No42¢

Yes ≈ 58% chance

$918 Vol▲ 0pts3y